Welcome to epgonline.org - the website for healthcare professionals

What's new?

  • ,Cystic Fibrosis Knowledge Centre

    Launch of the Cystic Fibrosis Knowledge Centre

    This new resource has been developed to support healthcare professionals
    in the treatment of patients with cystic fibrosis (CF).
    It contains a host of clinical information including a disease awareness section,
    emerging and supportive therapeutic options and current best practice
    based on recently updated guidelines by the
    European Cystic Fibrosis Society (ECFS).

  • ,CLL What's New

    New case-based chronic lymphocytic leukaemia
    CME module

    A new CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been
    added to the CLL Knowledge Centre on epgonline.org. Read case studies and improve
    your knowledge of CLL by answering quiz questions based on a variety of scenarios. This
    module has been EACCME-accredited and is worth 1 European CME credit. There is
    no cost to complete this educational activity.

  • ,Hypogonadism Relaunch Whats New

    Launch of updated Hypogonadism Knowledge Centre

    Our Hypogonadism Knowledge Centre contains important disease awareness
    information to support healthcare professionals in the current best practice
    treatment and management of male hypogonadism and is available to access free of
    charge. Sections cover epidemiology, pathophysiology, signs and symptoms, treatment
    options, as well as useful resources and a regularly updated publications digest.


  • ,

    New Type 2 Diabetes CME now available

    A new CME activity ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in
    Combination with Insulin’ has been added to the Type 2 Diabetes Learning Zone.
    Complete the five modules to enhance your understanding of the combination
    therapies available for treating type 2 diabetes.

  • ,COPD whats new ATS 2015

    ATS 2015 symposium materials added to
    COPD Knowledge Centre

    Speaker slides and a video from the Novartis-sponsored symposium ‘Are we gaining the
    maximum benefit from bronchodilators in COPD?’ have been added to the COPD Knowledge
    Centre. The session was held at the American Thoracic Society (ATS) conference 2015 to
    highlight the fundamental role of bronchodilators in COPD management, and presented
    key drug data including efficacy and safety of some of the latest COPD therapies.

Latest News

Sandoz files pegfilgrastim biosimilar at EMA for the same indication as the reference product Neulasta.


Sandoz has announced that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application (MAA) for its biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim) - a long-acting recombinant human granulocyte ...

Phase III study 309 results for Halaven (eribulin) in soft tissue sarcoma published in The Lancet- Eisai


Full results from the phase III study 309 have been published for the first time in The Lancet, and show Halaven (eribulin), from Eisai, improved median overall survival compared to dacarbazine for people with unresectable locally advanced ...

Alkermes initiates ENLIGHTEN-2 Phase III trial of ALKS 3831,(samidorphan + olanzapine) for schizophrenia.


Alkermes has announced the initiation of ENLIGHTEN-2 ,the second of two core phase III studies for ALKS 3831,(samidorphan + olanzapine) an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment ...

Mylan acquires Meda AB for $9.9 billion


Mylan N.V. a leading global pharmaceutical company announced a recommended public offer to the shareholders of Meda Aktiebolag to tender all their shares in Meda to Mylan. The total Offer consideration consists of a combination of cash and Mylan ...

FDA Arthritis Advisory Committee recommends CTP 13 (infliximab biosimilar) for all indications of the reference product - Hospira/Pfizer


The FDA Arthritis Advisory Committee has approved the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion's proposed biosimilar infliximab, to which Pfizer/Hospira holds exclusive ...

Phase III trial of elagolix in endometriosis meets primary endpoint- AbbVie/Neurocrine Biosciences


AbbVie and Neurocrine Biosciences have announced positive top-line results from the second of two replicate pivotal Phase III clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer pain from endometriosis. ...

New Drug Application for SB 1518 (pacritinib) for myelofibrosis withdrawn after FDA announces clinical hold on trials- CTI BioPharma


Following the partial clinical hold announced in February 2016 by the FDA regarding its clinical studies of SB 1518 (pacritinib) for myelofibrosis, CTI BioPharma received communication from the FDA notifying the Company that its IND for pacritinib ...

Recent Updates


Clinical Guidelines

Myeloma: diagnosis and management

Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over


Care of dying adults in the last days of life

Medical Journals


Imatinib: a breakthrough of targeted therapy in cancer.

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

epgonline.org Social

Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors